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Abstract
Introduction—Campylobacteriosis is one of the leading causes of gastroenteritis worldwide. 
This study describes the epidemiology of laboratory-confirmed Campylobacter diarrheal 
infections in two facility-based surveillance sites in Guatemala.
Methods—Clinical, epidemiologic, and laboratory data were collected on patients presenting 
with acute diarrhea from select healthcare facilities in the departments of Santa Rosa and 
Quetzaltenango, Guatemala, from January 2008 through August 2012. Stool specimens were 
cultured for Campylobacter and antimicrobial susceptibility testing was performed on a subset of 
isolates. Multidrug resistance (MDR) was defined as resistance to ≥3 antimicrobial classes.
Results—Campylobacter was isolated from 306 (6.0%) of 5137 stool specimens collected. For 
children <5 years of age, annual incidence was as high as 1288.8 per 100,000 children in Santa 
Rosa and 185.5 per 100,000 children in Quetzaltenango. Among 224 ambulatory care patients 
with Campylobacter, 169 (75.5%) received metronidazole or trimethoprim-sulfamethoxazole, and 
152 (66.7%) received or were prescribed oral rehydration therapy. Antimicrobial susceptibilities 
were tested in 96 isolates; 57 (59.4%) were resistant to ciprofloxacin and 12 (12.5%) were MDR.
Conclusion—Campylobacter was a major cause of diarrhea in children in two departments in 
Guatemala; antimicrobial resistance was high, and treatment regimens in the ambulatory setting 
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which included metronidazole and trimethoprim-sulfamethoxazole and lacked oral rehydration 
were sub-optimal.
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1. Introduction
Campylobacteriosis, usually acquired by the consumption and handling of poultry – is one 
of the leading causes of gastroenteritis worldwide [1]. The illness is characterized by 
diarrhea, abdominal cramps, and fever [2]. Although mortality is rare, significant post-
infectious sequelae such as Guillain–Barré syndrome, irritable bowel syndrome, and reactive 
arthritis do occur [3–6]. The utilization of fluoroquinolones in feed animals to treat illness 
and promote growth has contributed to increasingly quinolone-resistant Campylobacter 
strains [7,8], complicating the treatment for patients with severe disease and 
immunocompromised states, especially children [1].
In Guatemala, diarrhea is the second most common cause of morbidity and mortality in 
children <5 years of age [9]. Small, community-based studies in Guatemala suggest that 
Campylobacter is a common cause of diarrhea in children [10,11]. However, no estimates 
have been generated for the incidence of campylobacteriosis in Guatemala or for the degree 
of antimicrobial resistance. Identification of Campylobacter requires specific culturing 
techniques with micro-aerobic environments [12], and few laboratories in Guatemala 
routinely culture for this pathogen.
In this report, cases are characterized and the incidence of laboratory-confirmed 
campylobacteriosis is estimated from a facility-based surveillance system in Guatemala 
from 2008 through 2012.
2. Methods
2.1. Study sites
In July 2007, the U.S. Centers for Disease Control and Prevention’s (CDC) International 
Emerging Infections Program (IEIP) in Guatemala, in collaboration with the Ministry of 
Public Health and Welfare (MSPAS) and the Universidad del Valle de Guatemala (UVG), 
initiated a facility-based surveillance system in the department of Santa Rosa. Additional 
sites in the department of Quetzaltenango were added in February of 2009. The surveillance 
system captures patients of all ages in both ambulatory and hospital settings, and diarrhea is 
one of the syndromes under surveillance.
Santa Rosa, with a population of 346,590 persons, is one of 22 administrative departments in 
Guatemala, and it is located in the semi-tropical southern part of the country. Ethnically, the 
population is 15% Amerindian indigenous [13]. Quetzaltenango, with a population of 
789,358 persons, is in the western highlands and has a population that is 62% Amerindian 
indigenous. Government health facilities include hospitals, health centers staffed by a 
physician and nurses, and health posts staffed by nurses. In both surveillance sites, the 
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facility-based system includes a hospital and an ambulatory component. In Santa Rosa, the 
surveillance system includes the regional hospital in Cuilapa, the municipal capital of Santa 
Rosa, as well as the health center and five health posts of the municipality of Nueva Santa 
Rosa, located 30 km north of Cuilapa. In Quetzaltenango, surveillance includes the regional 
hospital in the capital of Quetzaltenango, as well as the three health centers and one health 
post in the municipalities around the capital. In this analysis, the health centers and health 
posts were collectively considered ambulatory care facilities, and cases captured in these 
facilities were used for ambulatory surveillance. Data were included from Santa Rosa 
between January 2008 and August 2012, and from Quetzaltenango between February 2009 
and August 2012.
2.2. Case detection and data collection
A case of diarrhea was defined as≥3 loose or liquid stools in a 24-h period with onset within 
the seven days preceding presentation to any participating facility by a patient residing in a 
municipality covered by the surveillance system. To avoid enrolling patients with chronic 
diarrhea, subjects were excluded if they had any signs or symptoms of diarrhea within the 
seven days prior to the onset of the current illness. Surveillance nurses screened patients by 
reviewing log book entries and assessing chief complaints for diarrhea-related visits and 
admissions. These patients were interviewed, and if found to meet the case definition, 
detailed clinical, epidemiologic, demographic, and socioeconomic data were obtained 
through structured patient interviews and medical chart abstractions [14]. In the ambulatory 
setting, facilities were staffed with surveillance nurses during all working hours and all 
patients presenting with diarrhea were screened for eligibility. In the hospital setting, except 
for holidays, surveillance nurses were on-duty seven days per week from 8:00 AM to 5:00 
PM. Only patients who were admitted to the hospital were screened for eligibility. This 
insured that only severe cases of diarrhea were enrolled in hospital surveillance, and it also 
was the only feasible approach since surveillance nurses were not able to collect all the 
necessary laboratory and epidemiologic data from patients in the emergency department 
(ED) before they were discharged.
2.3. Laboratory methods
A stool specimen was requested of all consenting patients. For children <5 years of age who 
were unable to produce a specimen, a rectal swab was collected and placed in Cary-Blair 
transport media. Stool samples from the ambulatory facilities were stored in Cary-Blair 
transport media in an insulated cooler at 4 °C, and transported within 24 h to one of the two 
regional hospitals for initial processing and testing. Samples were streaked by direct plating 
onto Campylobacter selective agar base, Karmali (Oxoid, Basingstoke, UK) and incubated 
at 42 °C for 48 h under microaerophilic conditions provided by the CampyGen™ 
Generating System (Oxoid, Basingstoke, UK). Small, gray, moist, and flat spreading 
colonies were considered suspicious of Campylobacter, and were placed on a stained slide 
for microscopic examination. On visual examination, colonies with “gull-winged,” spiral, or 
“S”-shaped structures were considered microscopically suspect colonies, and were 
subsequently plated on Mueller Hinton (Oxoid, Basingstoke, UK) or blood agar and tested 
with oxidase and catalase and the Dryspot Campylobacter test kit (Oxoid, Basingstoke, UK) 
to confirm Campylobacter. The hippurate test was used to identify C. jejuni [15]. A 
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specimen was considered negative for Campylobacter if no suspicious colonies grew after 
72 h of incubation. Isolates were sent to UVG laboratories for Campylobacter and C. jejuni 
confirmation and antimicrobial susceptibility testing. Due to limited supplies, antimicrobial 
susceptibility testing was performed on all cultures done from 2010 to 2011 that grew 
Campylobacter, using minimum inhibitory concentrations (MIC) via Etest® (Biomérieux, 
Marcy l’Etoile, France) for the following antimicrobial agents: nalidixic acid (NA), 
chloramphenicol, ciprofloxacin, erythromycin, and tetracycline [16]. Multidrug-resistance 
(MDR) was defined as resistance to at least one antimicrobial in at least three of the 
following antimicrobial groups: macrolides, quinolones, phenicol, and tetracycline [17,18].
2.4. Data analysis
The number of laboratory-confirmed Campylobacter infections was examined by quarter 
and stratified by ambulatory and hospital settings separately for Santa Rosa and 
Quetzaltenango. The total number of diarrhea cases that were captured by the surveillance 
system was also displayed per quarter. Seasonality of Campylobacter infections was 
assessed visually using time series graphs.
Annual crude rates for Campylobacter were calculated. Population denominators were 
obtained for the catchment area of the surveillance facilities by healthcare setting for all ages 
and for children <5 years, from 2000 through 2010 municipality data from Guatemala’s 
National Institute of Statistics (INE) [13]. Population estimates for the catchment areas in 
2011 and 2012 were generated by calculating the average change in municipality population 
by age from 2009 to 2010, then assuming that same change for 2011 and 2012.
Demographic and clinical characteristics of case–patients treated at ambulatory and hospital 
settings were compared using chi square tests. Fisher’s exact tests were used when cell sizes 
had counts of five or less. Demographic, geographic, healthcare setting, and clinical 
differences were explored between patients who had antimicrobial susceptibility data versus 
those who did not using chi square tests. The proportion resistant was calculated for each of 
the five tested antimicrobials for all Campylobacter and the subset of C. jejuni. In addition, 
the difference was tested in the proportion of isolates that were MDR from ambulatory 
versus hospital settings using Fisher’s exact test.
2.5. Ethics
The surveillance protocol was approved by the institutional review boards of the CDC and 
the UVG, and approved by the Guatemalan MSPAS. Verbal consent was requested of 
patients in order to screen them for eligibility. Written, informed consent was obtained from 
eligible patients who were willing to participate. For patients <18 years of age, parents or 
guardians were asked to provide written, informed consent for the participation of the 
patient. In addition, children aged 7 through 17 were asked for written, informed assent.
3. Results
During the five-year analysis period in Santa Rosa, 4327 patients met the case definition for 
diarrhea and all but one consented to participate; 246 (6.3%) of 3929 (90.8%) stool 
specimens collected yielded cultures positive for Campylobacter. During the three-year 
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analysis period in Quetzaltenango, 1336 patients met the case definition for diarrhea and all 
but one consented to participate; 60 (5.0%) of 1208 (90.4%) stool specimens collected 
yielded cultures positive for Campylobacter. No seasonal pattern of disease was evident by 
visual inspection of time series graphs. In the hospital setting in Santa Rosa during 2008 
through 2012, the median crude annual incidence of Campylobacter infections was 2.4 per 
100,000 persons (range, 0–6.6) for all ages, and 16.1 per 100,000 persons (range, 0–45.0) 
for children <5 years old (Table 1). Median incidence in the ambulatory setting in Santa 
Rosa was 149.5 per 100,000 persons (range, 92.5–215.8) for all ages, and 910.7 per 100,000 
persons (range, 594.5–1288.8) for children <5 years old. In the ambulatory setting in 
Quetzaltenango during 2010 through 2012, the median crude annual rate was 9.4 per 
100,000 persons (range, 8.5–27.3) for all ages, and 55.2 per 100,000 persons (range, 48.3–
185.5) for children <5 years old. Of the 306 Campylobacter cases, 235 (76.8%) were C. 
jejuni (Table 2).
During the study period, the number of laboratory-confirmed Campylobacter infections and 
diarrhea cases captured by the surveillance system per quarter varied, especially for Santa 
Rosa (Fig. 1a and b). In Santa Rosa, the median proportion of cases with a confirmed 
Campylobacter infection per stool culture performed per quarter was 8.0% (range, 0.4–
17.1%) in the ambulatory setting and 4.1% (range, 0–11.1%) in the hospital setting. In 
Quetzaltenango, the median proportion was 3.9% (range, 0–13.5%) in the ambulatory 
setting and 5.0% (range, 0–15.8%) in the hospital setting. The proportion of cases presenting 
to ambulatory versus hospital settings was higher for both Santa Rosa (86.6%) and 
Quetzaltenango (73.3%).
Over 40% of the Campylobacter infections occurred in children <1 year of age, over 90% in 
children <5 years (<50% of patients screened were <5 years of age) (Table 2). More patients 
presenting to the ambulatory versus hospital settings stated that they had abdominal pain or 
cramping (p = 0.0002). Over 40% of hospitalized versus 17.0% of ambulatory case–patients 
had an axillary temperature of ≥38 °C (p = 0.0002). A higher proportion of hospitalized 
case–patients showed signs of dehydration with somewhat or very dry oral mucosa (p < 
0.0001). Overall, 27 (8.8%) of the case–patients reported bloody diarrhea.
Among hospitalized case–patients, 45 (94.0%) received intravenous fluids; 4 (8.5%) were 
admitted to the intensive care unit, all were ≤6 months of age (Table 2). In the ambulatory 
setting, 152 patients (66.7%) received or were prescribed oral rehydration solution. Of the 
76 patients who did not receive oral rehydration solution in the ambulatory setting, 64 
(84.2%) were <5 years of age and 22 (34.4%) of them had sunken eyes, very dry mucosa, 
delayed capillary refill, or decreased skin turgor (data not shown). In the ambulatory setting, 
most patients (75.5%) received or were prescribed empiric therapy with metronidazole or 
trimethoprim-sulfamethoxazole. No patients died.
Antimicrobial susceptibility testing was performed on 96 (31.4%) of the 306 laboratory-
confirmed Campylobacter case isolates; there were no demographic, geographic, healthcare 
setting, or clinical differences between patients with and patients without antimicrobial 
susceptibility data. Most specimens were C. jejuni (67.7%). Chloramphenicol had the lowest 
resistance rates while the quinolones including nalidixic acid and ciprofloxacin had the 
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highest (Table 3). A total of 83 (86.4%) isolates were resistant to at least one antimicrobial 
class and 12 (12.5%) were MDR (Table 4). There was no difference in the proportion of 
isolates that were MDR in ambulatory versus hospital settings (p = 0.44); 9 (75.0%) of the 
12 macrolide-resistant strains were MDR (data not shown).
4. Discussion
This study is the first large study to describe laboratory-confirmed Campylobacter infections 
in Guatemala. In the ambulatory setting in Santa Rosa in 2010, crude annual incidence rates 
were as high as 215.8 per 100,000 for all ages, and 1288.8 per 100,000 in children <5 years 
old. Campylobacter primarily affected children <5 years of age, and most patients presented 
to ambulatory care centers for treatment. Among isolates tested, the proportion that was 
MDR was 12.5%.
In 2009 and 2010 the incidence of Campylobacter infections in the United States reported 
by FoodNet, which provides population-based estimates of laboratory-confirmed infections 
commonly transmitted through food from 10 sites, was 13.0 and 13.6 per 100,000 persons, 
respectively, for all ages [19,20]. In the ambulatory setting in Santa Rosa, crude incidence 
rates for all ages in 2009 and 2010 were 10-fold higher than corresponding rates in the 
United States in 2009 and 16-fold higher for 2010. For the United States in 2010, FoodNet 
reported the incidence among children <5 years old of 24.4 per 100,000 persons, while in 
Santa Rosa during that year, this study found an incidence of 1288.8 – over 50-fold greater 
[19]. The reported incidence rates in other parts of the world varied, including 400 per 
100,000 persons in New Zealand (2003) [21], >120 per 100,000 in Australia (2005) [22], 
44.1 per 100,000 in Europe (2008) [23], and 30 per 100,000 in Canada (2004) [24]. Rates 
from Quetzaltenango, Guatemala were lower than Santa Rosa. It is important to note that 
differences in the surveillance methodology may impact incidence rates.
Quinolone-resistant Campylobacter strains have been rising worldwide in the past two 
decades [1,6]. The proportion of Campylobacter isolates resistant to ciprofloxacin in the 
U.S. National Antimicrobial Resistance Monitoring System (NARMS) in 2010 was 22.4% 
[17]. In Finland (2003–2005), 45% of Campylobacter strains were resistant to ciprofloxacin 
[18]. In SENTRY, a worldwide laboratory surveillance network, 42.6% of Campylobacter 
strains from 10 medical centers in Latin America and 20 in Europe were resistant to 
ciprofloxacin in 2003 [25]. The data from this study, from April 2010 through December 
2011, show an even higher proportion of ciprofloxacin-resistance of 59.4%. In addition, 
whereas 2.1% of isolates reported in NARMS in 2010 were MDR, this study found 12.5% 
of isolates from the Guatemalan surveillance system to be MDR. Macrolide resistance 
prevalence in the U.S. has been low (≤3%) and steady over the past ten years. In Guatemala, 
resistance prevalence was fourfold (12.5%) higher compared with NARMS. Similar to 
Finnish data [18], strains that were macrolide-resistant tended to be MDR.
Although most Campylobacter infections are self-limited and do not require antimicrobial 
therapy, patients with severe infections, and those who are immunocompromised or 
pregnant may require antimicrobial treatment. This study’s data suggest that resistant strains 
of Campylobacter are prevalent, making antimicrobial agent selection difficult. In the 
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sentinel sites in Guatemala, >75% of patients in the ambulatory setting received 
metronidazole or trimethoprim-sulfamethoxazole, neither of which is effective against 
Campylobacter . At the same time, one-third of patients in the outpatient setting was not 
prescribed or did not receive oral rehydration solution. Of those, 84.2% were children <5 
years of age. One-third of those patients <5 years of age who had not received oral 
rehydration solution had at least one sign of dehydration on physical exam. These findings 
highlight the need to reemphasize the adequate training and performance monitoring of 
proper oral rehydration solution administration, especially among young vulnerable 
populations.
Similar to the geographic variation in campylobacteriosis in FoodNet sites in the U.S. [26], 
this study also found large differences in the rates of Campylobacter infections and the 
number of patients presenting with diarrhea in Santa Rosa and Quetzaltenango. The warm 
climate of Santa Rosa likely contributes to the higher rate of diarrheal disease in the 
department [27]. Differences in healthcare seeking behaviors and hospital admitting 
practices may also partially explain the difference. In the United States, campylobacteriosis 
is a seasonal disease that peaks in the summer months [26]. In Guatemala, a definitive 
seasonal pattern was not observed, perhaps because temperatures remain relatively stable 
throughout the year.
The findings of this study are subject to a number of limitations. Although the surveillance 
platform includes most of the government facilities in the populations studied, not all 
patients seek care in these facilities and some do not seek care at all. Therefore, the crude 
incidence rates are an underestimate of the true incidence of Campylobacter disease. In 
addition, surveillance in the hospital setting only includes patients who are admitted. Thus, 
patients seen in the ED and then discharged or transferred will not be included in this data, 
again leading to underestimates in the rate calculations. The presence of Campylobacter in 
healthy controls was not tested to determine what proportion of the cases identified in this 
surveillance system may have been asymptomatic carriers of Campylobacter whose disease 
was caused by another enteric pathogen. Finally, these data are from the departments of 
Santa Rosa and Quetzaltenango and therefore may not be generalizable to all of Guatemala. 
These data, however, are the most comprehensive description of campylobacteriosis in 
Guatemala and Central America in the healthcare setting.
5. Conclusion
Campylobacter is a major cause of diarrhea in children <5 years of age in Guatemala with 
disease rates in the ambulatory setting significantly higher than those of the United States. 
Consistent with the epidemiology of Campylobacter elsewhere, disease predominantly 
affected younger age groups. Similar to FoodNet data from the United States, rates varied 
substantially between sites, but unlike FoodNet, no seasonal pattern was apparent. Although 
treatment is normally supportive, one-third of patients in the outpatient setting was not 
prescribed or given oral rehydration therapy and >75% were given an antimicrobial 
ineffective against Campylobacter. Quinolone-resistant and MDR Campylobacter 
proportions were higher in Guatemala than in other countries, potentially complicating the 
treatment for immunocompromised and pregnant patients or those with severe disease. This 
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study illustrates the capacity of a sentinel healthcare facility-based surveillance system to 
provide working estimates of the incidence of an acute infectious disease. The next steps in 
addressing the burden of campylobacteriosis in Guatemala include the utilization of this 
platform to identify risk factors for Campylobacter infection through focused case–control 
studies; test interventions based on results of risk-factor studies, aimed at reducing the 
burden of disease; identify optimal treatment regimens for diarrhea in these populations; and 
establish the further burden of post-infectious sequelae of campylobacteriosis and the 
economic cost of the illness.
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Fig. 1a. Number of laboratory-confirmed Campylobacter cases and diarrhea cases per 
quarter-year by patient-care setting, Santa Rosa, Guatemala 2008–2012.
Fig. 1b. Number of laboratory-confirmed Campylobacter cases and diarrhea cases per 
quarter-year by patient-care setting, Quetzaltenango, Guatemala 2009–2012.
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Table 2
Characteristics of 306 laboratory-confirmed Campylobacter cases captured at Santa Rosa and Quetzaltenango 
surveillance sites, stratified by healthcare setting, January 1, 2008 to August 31, 2012.








Age in years 0.15
 <1 127 (41.5) 101 (39.3) 26 (53.1) a
 1–4 155 (50.7) 135 (52.5) 20 (40.8)
 5–18 11 (3.6) 11 (4.3) 0
 19–50 6 (2.0) 5 (2.0) 1 (2.0)
 >50 7 (2.3) 5 (2.0) 2 (4.1)
Male sex 171 (55.9) 148 (57.6) 23 (46.9) 0.17
History
Fever b 144 (53.3) 114 (51.4) 30 (62.5) 0.16
Bloody diarrhea 27 (8.8) 25 (9.7) 2 (4.1) 0.28 a
Abdominal pain/cramping b 145 (51.6) 136 (56.0) 9 (23.7) 0.0002
Clinical
Measured fever ≥ 38° C b 58 (21.3) 38 (17.0) 20 (40.8) 0.0002
Sunken eyes 104 (34.0) 86 (33.5) 18 (36.7) 0.66
Oral mucosa <.0001
 Somewhat dry 133 (43.5) 99 (38.5) 34 (69.4)
 Very dry 19 (6.2) 13 (5.1) 6 (12.2)
Prolonged capillary refill b 13 (4.5) 11 (4.5) 2 (4.2) 0.92
Decreased skin turgor b 5 (1.7) 5 (2.0) 0 1.00a
Laboratory speciation 0.82
Campylobacter jejuni 235 (76.8) 198 (77.0) 37 (75.5)
Campylobacter sp. – unknown 71 (23.2) 59 (23.0) 12 (24.5)
Treatment
Admitted to intensive care unit b,c 4 (8.5)
Received intravenous fluids b,c 45 (94.0)
Received or prescribed oral rehydration solution b,d 152 (66.7)
Received or prescribed medication b,d 214 (93.9)
 Azithromycin b 2 (0.9) 1 (2.7)
 Chloramphenicol 0 0
 Clindamycinb 0 0
 Ciprofloxacin b 3 (1.3) 0
 Doxycycline b 0 0
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 Erythromycin b 6 (3.2) 1 (2.7)
 Levofloxacin**b 0 0
 Metronidazole b 56 (25.0) 1 (2.7)




Proportions based on non-missing data.
c
Data only available in hospital setting.
d
Data only available in ambulatory setting.
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Table 3
Number and percentage of Campylobacter isolates resistant to antimicrobial agents, Santa Rosa and 
Quetzaltenango, Guatemala 2010–2011.
Antimicrobial class Antimicrobial All Campylobacter N = 96
n (%)
Campylobacter jejuni N = 65
n (%)
Macrolide Erythromycin 12 (12.5) 8 (12.3)
Quinolones Ciprofloxacin 57 (59.4) 42 (64.6)
Nalidixic acid 62 (66.7) 43 (68.3)
Phenicol Chloramphenicol 11 (11.5) 7 (10.8)
Tetracycline Tetracycline 59 (61.5) 41 (63.1)
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Table 4
Resistance patterns of Campylobacter isolates, Santa Rosa and Quetzaltenango, Guatemala 2010–2011.
Antimicrobial All Campylobacter N = 96
n (%)
Campylobacter jejuni N = 65
n (%)
No resistance 13 (13.5) 10 (15.4)
Resistance to one antimicrobial class 32 (33.3) 18 (27.7)
Resistance to two antimicrobial classes 39 (40.6) 29 (44.6)
Resistance to three antimicrobial classes 10 (10.4) 7 (10.8)
Resistance to four antimicrobial classes 2 (2.1) 1 (1.5)
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